CIAM
BEAM icon

Caitong International Asset Management’s Beam Therapeutics BEAM Stock Holding History

Caitong International Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
+15,840
New +$440K 0.07% 239
2025
Q2 		– Sell
-4,430
Closed -$86.5K – 2011
2025
Q1 		$86.5K Buy
+4,430
New +$116K 0.06% 323

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Caitong International Asset Management's BEAM Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Beam Therapeutics (BEAM) in Q1 2026: 15,840 shares worth $377K. The stake represents 0.07% of the portfolio and ranks #239 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in BEAM as recently as Q1 2025.

Caitong International Asset Management first reported a position in BEAM in Q1 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Caitong International Asset Management held 15,840 shares of Beam Therapeutics worth $377K as of Q1 2026.
  • Beam Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Beam Therapeutics made up 0.07% of Caitong International Asset Management's portfolio in Q1 2026, its #239 holding.
  • Caitong International Asset Management first reported a position in Beam Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.